Medidata Links Apple ResearchKit its Clinical Cloud®
Medidata announced the completion of an open-source connector linking Apple® ResearchKitTM with its Medidata Clinical Cloud® platform.
Medidata announced the completion of an open-source connector linking Apple® ResearchKitTM with its Medidata Clinical Cloud® platform. This will enable life sciences companies and academic institutions to map data generated by ResearchKit apps into Medidata’s secure, regulatory-compliant environment, integrating the data with other information collected in clinical trials. Medidata has released the source code for the connector on GitHub's open source community, to create connections between ResearchKit apps and the Medidata platform to help researchers, CROs and sponsors gather more and better data on patients’ health status and response to therapeutic interventions.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
